442 related articles for article (PubMed ID: 26433848)
21. Skin-Directed Therapies in Cutaneous T-Cell Lymphoma.
Nguyen CV; Bohjanen KA
Dermatol Clin; 2015 Oct; 33(4):683-96. PubMed ID: 26433841
[TBL] [Abstract][Full Text] [Related]
22. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
[TBL] [Abstract][Full Text] [Related]
23. Extracorporeal Photopheresis in Dermatological Diseases.
Terhaar H; Saleem M; Yusuf N
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474257
[TBL] [Abstract][Full Text] [Related]
24. Racial differences in the use of extracorporeal photopheresis for mycosis fungoides.
Agi C; Kuhn D; Chung J; Zampella J; Hinds G
J Dermatolog Treat; 2015 Jun; 26(3):266-8. PubMed ID: 25034002
[TBL] [Abstract][Full Text] [Related]
25. Photochemotherapy for mycosis fungoides: a clinical and histological study.
Lowe NJ; Cripps DJ; Dufton PA; Vickers CF
Arch Dermatol; 1979 Jan; 115(1):50-3. PubMed ID: 760657
[TBL] [Abstract][Full Text] [Related]
26. Treatment of advanced mycosis fungoides and Sézary syndrome with continuous infusions of methotrexate followed by fluorouracil and leucovorin rescue.
Schappell DL; Alper JC; McDonald CJ
Arch Dermatol; 1995 Mar; 131(3):307-13. PubMed ID: 7887660
[TBL] [Abstract][Full Text] [Related]
27. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
[TBL] [Abstract][Full Text] [Related]
28. Early changes in miRNA expression are predictive of response to extracorporeal photopheresis in cutaneous T-cell lymphoma.
McGirt LY; Baerenwald DA; Vonderheid EC; Eischen CM
J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2269-71. PubMed ID: 24909834
[No Abstract] [Full Text] [Related]
29. Mycosis fungoides and total skin electron beam radiation.
Jones GW; Wilson LD
Blood; 1997 Apr; 89(8):3062-4. PubMed ID: 9108429
[No Abstract] [Full Text] [Related]
30. Extracorporeal photopheresis in Sézary syndrome. No significant effect in the survival of 44 patients with a peripheral blood T-cell clone.
Fraser-Andrews E; Seed P; Whittaker S; Russell-Jones R
Arch Dermatol; 1998 Aug; 134(8):1001-5. PubMed ID: 9722731
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
Kim YH; Bishop K; Varghese A; Hoppe RT
Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601
[TBL] [Abstract][Full Text] [Related]
32. Extracorporeal photochemotherapy induces apoptosis of infiltrating lymphoid cells in patients with mycosis fungoides in early stages. A quantitative histological study.
Miracco C; Rubegni P; De Aloe G; D'Ascenzo G; Mazzatenta C; De Santi MM; Fimiani M
Br J Dermatol; 1997 Oct; 137(4):549-57. PubMed ID: 9390330
[TBL] [Abstract][Full Text] [Related]
33. Targeted therapies for cutaneous T-cell lymphomas.
Kaplan JB; Guitart J; Giles FJ
Expert Rev Hematol; 2014 Aug; 7(4):481-93. PubMed ID: 25025372
[TBL] [Abstract][Full Text] [Related]
34. New and established treatment options for mycosis fungoides and Sézary syndrome - an update.
Dugas-Breit S; Schulze HJ; Hallermann C
J Dtsch Dermatol Ges; 2014 Jul; 12(7):561-9. PubMed ID: 24889480
[TBL] [Abstract][Full Text] [Related]
35. Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017-2019.
Girardi M; Carlson K; Huang X; Corman SL; Edmundson P; Schmier J; Kale HP; Raina R; Foss F
J Dermatolog Treat; 2024 Dec; 35(1):2360568. PubMed ID: 38852942
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now?
Scarisbrick JJ; Kim YH; Whittaker SJ; Wood GS; Vermeer MH; Prince HM; Quaglino P
Br J Dermatol; 2014 Jun; 170(6):1226-36. PubMed ID: 24641480
[TBL] [Abstract][Full Text] [Related]
37. Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment.
Alberti-Violetti S; Talpur R; Schlichte M; Sui D; Duvic M
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e105-12. PubMed ID: 25817937
[TBL] [Abstract][Full Text] [Related]
38. Extracorporeal photochemotherapy in mycosis fungoides.
Atilla E; Atilla PA; Bozdag SC; Yuksel MK; Toprak SK; Topcuoglu P; Akay BN; Sanli H; Akan H; Demirer T; Beksac M; Arslan O; Ozcan M; Gurman G; Ilhan O
Transfus Clin Biol; 2017 Nov; 24(4):454-457. PubMed ID: 28578935
[TBL] [Abstract][Full Text] [Related]
39. Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors.
Quadri I; Reneau JC; Hanel W; Chung CG
Front Immunol; 2023; 14():1291259. PubMed ID: 38022633
[TBL] [Abstract][Full Text] [Related]
40. Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group.
Molin L; Thomsen K; Volden G; Aronsson A; Hammar H; Hellbe L; Wantzin GL; Roupe G
Acta Derm Venereol; 1987; 67(3):232-6. PubMed ID: 2442936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
